Abingworth LLP

Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more

Plus: Gilead acquires Xilio’s IL-12 program and Harmonic-Turbine to co-develop dark kinase therapy for cancer

With important work ahead for ADC in lung cancer, Gilead strikes co-development deal with Carlyle-owned life sciences firm

Recap of practice-changing ESMO data, progress confirming an NIH director and latest from the IRA

With some biopharmas strapped for cash to fund Phase III programs, PE-backed firm’s co-investment fund now supplements co-development fund

Plus: Abingworth adds Joy Ghosh as managing director and Renibus hires Ramdas as SVP

Dynamics include increased growth capital, shifting opportunities in company creation

Ending a 49-year run as an independent firm, Abingworth will gain Carlyle’s resources to invest in expensive co-development programs

Plus: JPM goes virtual, Genenta’s IPO and updates from Travere, Boehringer, Sobi-Apellis, J&J,  Calliditas and more

Plus: new CBO, board member at Caribou, Nordic, GT Biopharma and more